Business Wire

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

Share

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. Boehringer Ingelheim aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments.

“Boehringer Ingelheim believes that these promising antibodies in-licensed from A*STAR will help us advance potent therapeutic candidates against key molecular cancer targets,” says Clive R. Wood, Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim and continues: “We look forward to developing these assets for a broad range of cancers with the goal to deliver breakthrough opportunities for patients.”

Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies). One tumor cell-directed modality is antibody drug conjugates, which allows for delivery of toxins directly into tumor cells. Another is T-cell engagers facilitating direct contact between T-cells and tumor cells, leading to T-cell-mediated killing of the tumor. Both technologies are directed towards markers on the surface of cancer cells, also known as antigens, in order to attack tumor cells but spare healthy tissues.

The innovative antibodies from A*STAR can potentially enable the development of safer, more efficacious therapies as they selectively bind to antigens that are highly expressed on tumor cells but are absent on normal healthy tissues.

Under the terms of the agreement, Boehringer Ingelheim will be responsible for further research, preclinical and clinical development as well as commercialization of targeted cancer therapies using the antibodies from A*STAR. A*STAR may receive payments totalling >100 million EUR in upfront and success-based development and commercialization milestones.

The technology used to identify the unique A*STAR antibodies resulted from a multi-institutional collaboration in Singapore. A*STAR’s Genome Institute of Singapore (GIS) and Institute of Bioengineering & Bioimaging (IBB) generated antibodies which exclusively target antigens that were initially identified from gastric cancer cells. Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by A*STAR, then optimized the antibodies and confirmed their applicability to a range of other solid cancers. EDDC also demonstrated the utility of these antibodies in directing different therapeutic modalities selectively to cancer cells.

Professor Damian O'Connell, Chief Executive Officer of EDDC, says, “As Singapore's national drug discovery and development platform, EDDC is proud to translate great science in Singapore into valuable assets that can enable the precise treatment of cancer. We believe that Boehringer Ingelheim, with its broad expertise and technologies, is the right partner to maximize the potential of these antibodies for the development of safer, more targeted therapies for cancer patients.”

Professor Tan Sze Wee, Assistant Chief Executive (Enterprise) of A*STAR, says, “These antibodies were developed in Singapore through close collaboration across multiple institutions. There was also strong support by the Singapore Gastric Cancer Consortium. The agreement is testament to the best-in-class research taking place in Singapore. Cancer is a devastating disease, and we hope the fruits of our research can improve patient outcomes.”

Please click on the link for “Note to Editors’ and ‘References’:

https://www.boehringer-ingelheim.com/partnering/human-health-partnering/license-deal-astar-develop-cancer-antibodies

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media queries and clarifications:

Dr. Reinhard Malin
Innovation Unit Communications
Corporate Affairs
Boehringer Ingelheim
Tel: +49 6132 77-90815
Email: reinhard.malin@boehringeringelheim.com

Owen Sia
Assistant Head, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6517 7866
Email: owen_sia@hq.a-star.edu.sg

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Introduces S3NS in Partnership With Google Cloud and Unveils Its Offering in a First Step Towards the French Trusted Cloud Label30.6.2022 14:20:00 CEST | Press release

Thales announced today the creation of S3NS, a French company designed to offer public and private organizations in France the power of Google Cloud, fully compliant with France's “Trusted Cloud” label, in partnership with Google Cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005160/en/ (Graphic: Thales) The new company, majority owned and controlled by Thales, is under French law and follows the October 2021 partnership announcement between Thales and Google Cloud to jointly develop a locally-compliant Trusted Cloud offering. Thales and Google Cloud are committed to helping companies and public institutions to innovate and accelerate their digital transformation in ways that afford autonomy, compliant sovereignty, and the greatest possible benefits for their customers and users. Meeting the French “Trusted Cloud” S3NS will offer from the second half of 2024 its “trusted cloud” offering that will ultimately comb

ExaGrid Named to First-Ever MES Matters – Key Vendors Serving the Midmarket List30.6.2022 14:00:00 CEST | Press release

ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced that Midsize Enterprise Services (MES), a brand of The Channel Company, has recognized ExaGrid on its 2022 MES Matters- Key Vendors Serving the Midmarket list. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005185/en/ (Graphic: Business Wire) The MES Matters list recognizes vendors that have proven themselves to be forward-thinking technology providers offering solutions that support the growth and innovation of midmarket organizations. MES defines the midmarket as an organization with an annual revenue of $50M-$2B and/or 100-2500 total supported users/seats. Companies were selected due to their go-to-market strategy, how they serve the midmarket, and the strength of their midmarket product portfolios. ExaGrid focuses on the Midmarket to the Large Enterprise and offers the most value to customers who back up 50TB to 100s of PB of data, and ke

Leveraging the power of the cloud, Managed File Transfer helps organizations modernize and deliver value in an always-on world30.6.2022 14:00:00 CEST | Press release

Axway (Euronext: AXW.PA), a leader in API-driven B2B integration and MFT software, is pleased to announce its newest release of Axway Managed File Transfer (MFT), available in both the Microsoft Azure and Amazon Web Services Cloud. As the demand and complexity of data transfers continue to grow in a post-pandemic world, companies need trusted solutions to mitigate the risks of cyber threats, legacy system obsolescence, and a shortage of human resources. “Managing mission-critical dataflows requires a more modern approach,” says Meetesh Patel, General Manager of Managed File Transfer at Axway. “Many of the largest banks, retailers, and auto manufacturers in the world already rely on us to power their operations. With Axway MFT, businesses can control more data at scale with security, resiliency, and speed while empowering their business users and satisfying regulatory and governance requirements.” Businesses are adapting to doing business in an always-on world, and time-trusted solution

Yagi & Co., Ltd. : Textile E-commerce Site Fably Further Improves as a Platform by Launching Services to Handle International Orders30.6.2022 12:00:00 CEST | Press release

Fably (https://www.fably.jp), a textile e-commerce site operated by YAGI & CO., LTD, (TOKYO:7460) (https://www.yaginet.co.jp/en/) aims to create a future of new manufacturing technologies through the use of digital technology to connect people in all fields of the textile industry under the concept of a “professional tool for textile”. In addition to product introductions, the site also features a broad range of other content in order to provide valuable information for experts in textile business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005055/en/ Main Image (Graphic: Business Wire) Previously, Fably had only handled orders from within Japan, but the site is now able to handle international orders as well. Participating Companies Currently, 33 companies in total offer their products through the site. The varieties of products available have increased in stages over time, from easy-to-use plain and patterned fab

Vita Mojo Raises US$30 Million to Help Restaurant and Hospitality Chains in Europe Tackle the Digital Future30.6.2022 12:00:00 CEST | Press release

Vita Mojo, the European leader in “front-of-house” restaurant software powering digital ordering and the management of smarter, more-efficient kitchen and delivery operations, has raised US$30 million in new financing to refine its product and expand into new markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005213/en/ Vita Mojo Co-Founders Nick Popovici (left) and Stefan Catoiu. (Photo: Business Wire) The funding round was led by global technology investment firm Battery Ventures, an investor in a number of U.S.-based restaurant and hospitality-tech companies including Olo* and CrunchTime! Information Systems*. Battery General Partner Morad Elhafed and Principal Zak Ewen will join Vita Mojo’s board. Vita Mojo – which sells to restaurants, pubs, coffee shops, bakeries and fast-casual eateries – counts large chains among its customer base including Nando’s, GAIL’s Bakery, Le Pain Quotidien, LEON, JKS Group and Nea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom